Which has better valuation and earnings, KPRX or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kiora Pharmaceuticals N/A N/A -$10.84M -$2.71 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A

Is KPRX or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -59.30% -41.23% Estrella Immunopharma N/A N/A -397.36%

Does the media favor KPRX or ESLA?

In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 2 articles in the media. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Estrella Immunopharma's score of 0.94 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiora Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GOSS or KPRX?

In the previous week, Gossamer Bio and Gossamer Bio both had 2 articles in the media. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Gossamer Bio's score of 0.93 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiora Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ACTU or KPRX?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Kiora Pharmaceuticals N/A N/A -$10.84M -$2.71 N/A

Is ACTU or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -59.30% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Kiora Pharmaceuticals N/A -59.30% -41.23%

Does the media prefer ACTU or KPRX?

In the previous week, Actuate Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for Actuate Therapeutics and 2 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Actuate Therapeutics' score of 0.62 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiora Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate KPRX or MIRA?

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 292.16%. Given Kiora Pharmaceuticals' higher probable upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, KPRX or MIRA?

Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kiora Pharmaceuticals N/A N/A -$10.84M -$2.71 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is KPRX or MIRA more profitable?

Kiora Pharmaceuticals' return on equity of -59.30% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -59.30% -41.23% MIRA Pharmaceuticals N/A -140.82% -135.01%

Kiora Pharmaceuticals (KPRX) Competitors

$2.55 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.53 -0.02 (-0.78%)

As of 09:22 AM Eastern

Compare

KPRX vs. ESLA, NBRV, GOSS, ACTU, and MIRA

Should you buy Kiora Pharmaceuticals stock or one of its competitors? MarketBeat compares Kiora Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kiora Pharmaceuticals include Estrella Immunopharma (ESLA), Nabriva Therapeutics (NBRV), Gossamer Bio (GOSS), Actuate Therapeutics (ACTU), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry.

How does Kiora Pharmaceuticals compare to Estrella Immunopharma?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Kiora Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	N/A	N/A	-$10.84M	-$2.71	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 2 articles in the media. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Estrella Immunopharma's score of 0.94 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiora Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 292.16%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 654.72%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Estrella Immunopharma's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Estrella Immunopharma	N/A	N/A	-397.36%

Summary

Kiora Pharmaceuticals and Estrella Immunopharma tied by winning 5 of the 10 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Nabriva Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Kiora Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Kiora Pharmaceuticals' return on equity of -59.30% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Kiora Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 292.16%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kiora Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for Nabriva Therapeutics. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Nabriva Therapeutics' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Positive
Nabriva Therapeutics	Neutral

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kiora Pharmaceuticals has higher earnings, but lower revenue than Nabriva Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	N/A	N/A	-$10.84M	-$2.71	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Summary

Kiora Pharmaceuticals beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Kiora Pharmaceuticals has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Gossamer Bio has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market.

In the previous week, Gossamer Bio and Gossamer Bio both had 2 articles in the media. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Gossamer Bio's score of 0.93 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiora Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kiora Pharmaceuticals has lower revenue, but higher earnings than Gossamer Bio. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.78	-$170.37M	-$0.79	N/A
Kiora Pharmaceuticals	N/A	N/A	-$10.84M	-$2.71	N/A

Gossamer Bio presently has a consensus target price of $5.00, suggesting a potential upside of 2,988.33%. Kiora Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 292.16%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 3.7% of Gossamer Bio shares are held by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Gossamer Bio beats Kiora Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Kiora Pharmaceuticals	N/A	N/A	-$10.84M	-$2.71	N/A

Actuate Therapeutics has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.4, meaning that its stock price is 140% less volatile than the broader market.

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Kiora Pharmaceuticals' return on equity of -59.30% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%

Actuate Therapeutics presently has a consensus price target of $17.50, suggesting a potential upside of 766.34%. Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 292.16%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Actuate Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for Actuate Therapeutics and 2 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat Actuate Therapeutics' score of 0.62 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiora Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Actuate Therapeutics beats Kiora Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to MIRA Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 1 mentions for MIRA Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.33 beat MIRA Pharmaceuticals' score of 0.94 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Positive
MIRA Pharmaceuticals	Positive

Kiora Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	N/A	N/A	-$10.84M	-$2.71	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 292.16%. Given Kiora Pharmaceuticals' higher probable upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kiora Pharmaceuticals' return on equity of -59.30% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-59.30%	-41.23%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

Summary

Kiora Pharmaceuticals beats MIRA Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPRX vs. The Competition

Export

Metric	Kiora Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.30M	$2.99B	$6.52B	$12.05B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-0.94	18.84	24.00	24.42
Price / Sales	N/A	455.32	533.77	123.88
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	0.58	3.98	10.55	6.82
Net Income	-$10.84M	$75.79M	$3.57B	$337.56M
7 Day Performance	-1.16%	1.57%	0.59%	1.16%
1 Month Performance	2.00%	-0.73%	1.55%	3.16%
1 Year Performance	-15.56%	23.44%	25.41%	30.60%

Kiora Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPRX Kiora Pharmaceuticals	3.6423 of 5 stars	$2.55 flat	$10.00 +292.2%	-15.6%	$11.30M	N/A	N/A	10	Positive News
ESLA Estrella Immunopharma	2.8161 of 5 stars	$1.07 -1.4%	$8.00 +651.2%	+10.4%	$45.83M	N/A	N/A	N/A	Gap Up
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70	Gap Up
GOSS Gossamer Bio	2.3495 of 5 stars	$0.19 -5.9%	$5.00 +2,555.3%	-86.9%	$44.19M	$48.47M	N/A	180	Gap Up
ACTU Actuate Therapeutics	2.0528 of 5 stars	$1.82 -3.2%	$17.50 +861.5%	-76.6%	$43.55M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. ESLA, NBRV, GOSS, ACTU, and MIRA

How does Kiora Pharmaceuticals compare to Estrella Immunopharma?

Summary

How does Kiora Pharmaceuticals compare to Nabriva Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to Gossamer Bio?

Summary

How does Kiora Pharmaceuticals compare to Actuate Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to MIRA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. ESLA, NBRV, GOSS, ACTU, and MIRA

How does Kiora Pharmaceuticals compare to Estrella Immunopharma?

Which has more volatility & risk, KPRX or ESLA?

Which has better valuation and earnings, KPRX or ESLA?

Does the media favor KPRX or ESLA?

Do analysts recommend KPRX or ESLA?

Do institutionals and insiders hold more shares of KPRX or ESLA?

Is KPRX or ESLA more profitable?

Summary

How does Kiora Pharmaceuticals compare to Nabriva Therapeutics?

Is KPRX or NBRV more profitable?

Do analysts prefer KPRX or NBRV?

Which has more risk & volatility, KPRX or NBRV?

Does the media refer more to KPRX or NBRV?

Do insiders & institutionals have more ownership in KPRX or NBRV?

Which has preferable valuation & earnings, KPRX or NBRV?

Summary

How does Kiora Pharmaceuticals compare to Gossamer Bio?

Is GOSS or KPRX more profitable?

Which has more risk and volatility, GOSS or KPRX?

Does the media refer more to GOSS or KPRX?

Which has stronger earnings and valuation, GOSS or KPRX?

Do analysts prefer GOSS or KPRX?

Do institutionals and insiders have more ownership in GOSS or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Actuate Therapeutics?

Which has higher earnings and valuation, ACTU or KPRX?

Which has more volatility & risk, ACTU or KPRX?

Do institutionals & insiders hold more shares of ACTU or KPRX?

Is ACTU or KPRX more profitable?

Do analysts recommend ACTU or KPRX?

Does the media prefer ACTU or KPRX?

Summary

How does Kiora Pharmaceuticals compare to MIRA Pharmaceuticals?

Does the media favor KPRX or MIRA?

Which has more risk & volatility, KPRX or MIRA?

Which has stronger valuation & earnings, KPRX or MIRA?

Do insiders & institutionals hold more shares of KPRX or MIRA?

Do analysts rate KPRX or MIRA?

Is KPRX or MIRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools